Global Blood Therapeutics, Inc. (GBT)

41.40
0.05 0.12
NASDAQ
Prev Close 41.45
Day Low/High 0.00 / 0.00
52 Wk Low/High 24.02 / 68.05
Exchange NASDAQ
Shares Outstanding 51.83B
Market Cap 2.18B
Div & Yield N.A. (N.A)

Latest News

First Week Of August 17th Options Trading For Global Blood Therapeutics (GBT)

First Week Of August 17th Options Trading For Global Blood Therapeutics (GBT)

Investors in Global Blood Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new August 17th contracts and identified one put and one call contract of particular interest.

Even Momentum Traders Should Study Stock Charts

Even Momentum Traders Should Study Stock Charts

You don't have to 'believe' in technical analysis to use it to set your exit and entry points.

Many Names on My Radar

Many Names on My Radar

There is no question that we are becoming extended and ripe for some profit taking.

Having Some Good Luck With Biotech Names

Having Some Good Luck With Biotech Names

Overall it is still a positive day but the action is sloppy.

Markets Make an Art of Unpredictability

Markets Make an Art of Unpredictability

Oil isn't the only reason stocks are higher.

Markets Confused by Trump's Upcoming Iran Decision

Markets Confused by Trump's Upcoming Iran Decision

No matter what happens with Iran, it is not going to be a major market positive.

Interesting GBT Put And Call Options For July 20th

Investors in Global Blood Therapeutics Inc saw new options become available today, for the July 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 87 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

GUERBET : 2017 Annual Results

GUERBET : 2017 Annual Results

5 Stocks That Are Showing Signs of Reversing

5 Stocks That Are Showing Signs of Reversing

These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.

GBT Appoints Industry Leader David L. Johnson As Chief Commercial Officer

GBT Appoints Industry Leader David L. Johnson As Chief Commercial Officer

Appointment Strengthens Management Team as Company Advances Clinical Development of Voxelotor, a Potential Disease-Modifying Therapy for Sickle Cell Disease

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

It is important to note that watching for a reversal is much different than being short.

The Confidence in the Dip Buyers Has Weakened

The Confidence in the Dip Buyers Has Weakened

The bears are likely to be increasingly bold if there's a failed bounce.

This Market Badly Needs a Rest

This Market Badly Needs a Rest

It would be a longer-term positive if the overbought conditions are alleviated.

The Stock Market Is Facing One Big Obstacle Right Now

The Stock Market Is Facing One Big Obstacle Right Now

You have to wonder how much longer we can run without a pullback of at least 2%.

Selling Action Is Upon Us

Selling Action Is Upon Us

There is still a very strong appetite for individual stocks with momentum.

Notable Tuesday Option Activity: GBT, SFM, CROX

Notable Tuesday Option Activity: GBT, SFM, CROX

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 6,399 contracts has been traded thus far today, a contract volume which is representative of approximately 639,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of GBT's average daily trading volume over the past month, of 1.5 million shares.

GBT Receives FDA Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease (SCD)

GBT Receives FDA Breakthrough Therapy Designation For Voxelotor For Treatment Of Sickle Cell Disease (SCD)

Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation